Aug 19th 2013 - Edison Investment Research today published a report on Evotec entitled "A Year Of Two Halves". In summary, the report says:
Evotec is expecting to have a strong H213 after an uncharacteristically quiet H113. Sales fell by 13% during the first half of the year, but Evotec still expects to deliver revenue growth of c 10% for the full year because of milestone/upfront payments in H213. It also aims to partner a preclinical asset, form at least one major alliance and form new CureX initiatives, all of which should help drive the long-term growth of the company. We have increased our valuation from €438m to €451m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »